Xavier Bofill-De Ros

Dr. Xavier Bofill-De Ros

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2023 in RNA Biology
Verified
Journal Article
Open access
Xavier Bofill-De RosXavier Bofill-De Ros
Xavier Bofill-De Ros
UØUlf Ørom
Ulf Ørom
MicroRNAs are a class of small regulatory RNAs that mediate regulation of protein synthesis by recognizing sequence elements in mRNAs. MicroRNAs are processed through a series of steps starting from transcription and primary processing in the nucleus to precursor processing and mature function in the cytoplasm. It is also in the cytoplasm where levels of mature microRNAs can be modulated through decay mechanisms. Here, we review the recent progress in the lifetime of a microRNA at all steps required for maintaining their homoeostasis. The increasing knowledge about microRNA regulation upholds great promise as therapeutic targets.

1 July 2016 in Methods
Verified
Journal Article
Closed access
Xavier Bofill-De RosXavier Bofill-De Ros
Xavier Bofill-De Ros
SGShuo Gu
Shuo Gu

1 August 2019 in Molecular Cell
Verified
Journal Article
Closed access
AYAcong Yang
Acong Yang
Xavier Bofill-De RosXavier Bofill-De Ros
Xavier Bofill-De Ros
TSTie-Juan Shao
Tie-Juan Shao
MJMinjie Jiang
Minjie Jiang
KLKatherine Li
Katherine Li
SGShuo Gu
Shuo Gu

2 June 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
AYAcong Yang
Acong Yang
TSTie-Juan Shao
Tie-Juan Shao
Xavier Bofill-De RosXavier Bofill-De Ros
Xavier Bofill-De Ros
CLChuanjiang Lian
Chuanjiang Lian
PVPatricia Villanueva
Patricia Villanueva
SGShuo Gu
Shuo Gu
MicroRNAs (miRNAs) associated with Argonaute proteins (AGOs) regulate gene expression in mammals. miRNA 3’ ends are subject to frequent sequence modifications, which have been proposed to affect miRNA stability. However, the underlying mechanism is not well understood. Here, by genetic and biochemical studies as well as deep sequencing analyses, we find that AGO mutations disrupting miRNA 3’ binding are sufficient to trigger extensive miRNA 3’ modifications in HEK293T cells and in cancer patients. Comparing these modifications in TUT4, TUT7 and DIS3L2 knockout cells, we find that TUT7 is more robust than TUT4 in oligouridylating mature miRNAs, which in turn leads to their degradation by the DIS3L2 exonuclease. Our findings indicate a decay machinery removing AGO-associated miRNAs with an exposed 3’ end. A set of endogenous miRNAs including miR-7, miR-222 and miR-769 are targeted by this machinery presumably due to target-directed miRNA degradation.

20 October 2018 in Gut
Verified
Journal Article
Closed access
PDF file
JLJeroni Luna
Jeroni Luna
JBJacopo Boni
Jacopo Boni
Miriam CuatrecasasMiriam Cuatrecasas
Miriam Cuatrecasas
Xavier Bofill-De RosXavier Bofill-De Ros
Xavier Bofill-De Ros
ENEstela Núñez-Manchón
Estela Núñez-Manchón
CFCristina Fillat
Cristina Fillat
Background and aims: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumour with a poor prognosis using current treatments. Targeted therapies may offer a new avenue for more effective strategies. Dual-specificity tyrosine regulated kinase 1A (DYRK1A) is a pleiotropic kinase with contradictory roles in different tumours that is uncharacterised in PDAC. Here, we aimed to investigate the role of DYRK1A in pancreatic tumorigenesis. Design: We analysed DYRK1A expression in PDAC genetic mouse models and in patient samples. DYRK1A function was assessed with knockdown experiments in pancreatic tumour cell lines and in PDAC mouse models with genetic reduction of Dyrk1a dosage. Furthermore, we explored a mechanistic model for DYRK1A activity. Results: We showed that DYRK1A was highly expressed in PDAC, and that its protein level positively correlated with that of c-MET. Inhibition of DYRK1A reduced tumour progression by limiting tumour cell proliferation. DYRK1A stabilised the c-MET receptor through SPRY2, leading to prolonged activation of extracellular signal-regulated kinase signalling. Conclusions: These findings reveal that DYRK1A contributes to tumour growth in PDAC, at least through regulation of c-MET accumulation, suggesting that inhibition of DYRK1A could represent a novel therapeutic target for PDAC.

1 April 2020 in Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms
Verified
Journal Article
Closed access
Xavier Bofill-De RosXavier Bofill-De Ros
Xavier Bofill-De Ros
AYAcong Yang
Acong Yang
SGShuo Gu
Shuo Gu